Maxim initiated coverage of Silexion Therapeutics (SLXN) with a Buy rating and $1 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SLXN: Silexion Therapeutics reports breakthroughs from SIL-204 preclinical studies Silexion Therapeutics announces new findings from Loder trial